InvestorsHub Logo
Followers 30
Posts 2785
Boards Moderated 3
Alias Born 10/24/2015

Re: NY1972 post# 344

Monday, 11/27/2023 8:57:29 PM

Monday, November 27, 2023 8:57:29 PM

Post# of 381
Yes, that was one of at least five (from memory) trials testing aNKs (non-engineered NK-92s).

In metastatic pancreatic IBRX tested low-dose nab-paclitaxel, gemcitabine, aldoxorubicin, cyclophosphamide, low-dose SBRT, N-803 (an IL-15 superagonist) and PD-L1 CAR-NKs.

In all patients (3rd to 6th line) mOS is 5.8 months; median PFS 2.3 months. In 3rd line, mOS is 6.3 months. While this exceeds historical results, there were no controls.

Going forward (for other types), they plan on adding a number of other agents, including a heterologous prime-boost vaccine.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FATE News